Coronavirus live news: New Zealand places limits on citizen returns as US cases near 3mJuly 7, 2020
South Africa’s cases pass 200,000; Kenya emerges from lockdown; Brazilian President Jair Bolsonaro tested again for coronavirus. Follow the latest updates
- US cases near 3m as White House claims country is a “leader” in global fight against virus
- Fury as Boris Johnson accuses care homes over high Covid-19 death toll
- New Zealand rations places for citizens returning home during Covid-19
- World map: which countries have the most cases and deaths?
The ABC reports that the state of Victoria in Australia, which is fighting a worsening coronavirus outbreak, has confirmed 191 new cases overnight, breaking yesterday’s record of 127 cases.
#BREAKING: Victoria has recorded 191 new cases of coronavirus – another record day for the state. Premier Daniel Andrews is due to hold a press conference this afternoon. @abcnews #COVID19Vic
China’s Sinovac Biotech is starting Phase III trials of its potential coronavirus vaccine in Brazil, it said on Monday, becoming one of three companies to move into the late stages in the race to develop an inoculation against the disease.
It follows a fast-track approval for the trials by Brazilian regulators last week.
Sinovac said the study, which will be done in partnership with Brazilian vaccine producer the Instituto Butantan, would recruit nearly 9,000 healthcare professionals working in COVID-19 specialised facilities and start this month.
AstraZeneca’s experimental Covid-19 vaccine, developed by researchers at the University of Oxford, and China National Pharmaceutical Group (Sinopharm) are the only other candidates in late-stage Phase III trials.
Moderna also plans to start its late-stage trial this month.
The World Health Organization says there are 19 vaccine trials in clinical evaluation and hundreds being developed and tested around the world to stop the Covid-19 pandemic.
No Covid-19 vaccine has yet been approved for commercial use. A Massachusetts Institute of Technology analysis last year found that about one in three vaccines in the first stage of testing later gains approval.